Biocon's Kiran Mazumdar Shaw On Q3 Results

Interview: Biocon's Chairman MD: Kiran Mazumdar-Shaw

Biocon's Kiran Mazumdar-Shaw Gives A Reality Check On Ease Of Doing Business In India

Look forward to an IPO in next 18-24 months, says Biocon’s Kiran Mazumdar Shaw

Q2WithBQ With Biocon's Kiran Mazumdar Shaw

Profit Insights | Biocon's Kiran Mazumdar Shaw Exclusive | NDTV Profit

Corporate tax cut is a much needed reform, says Biocon's Kiran Mazumdar Shaw

Biocon’s Kiran Mazumdar Shaw On Who’ll Win The Battle Between ‘Innovators’ And Biosimilar Makers

kiran-mazumdar-shaw-at-global-technology-summit

Q4 Review: Biocon's Kiran Mazumdar Shaw On Earnings & FY23 Projections

Kiran Mazumdar Shaw On Fighting and Recovering From COVID-19: ‘Dont Panic, Be Positive

Kiran Mazumdar-Shaw | Philanthropic focus on research

Kiran Mazumdar Shaw Backs Sikka & Team

Kiran Mazumdar Shaw of Biocon on business outlook

Kiran Mazumdar Shaw: The entrepreneur ahead of her time

It's a very welcome move: Kiran Mazumdar-Shaw on WHO's nod for Covaxin

Kiran Mazumdar-Shaw | Advice to new philanthropists: where can you make a difference?

Kiran Mazumdar-Shaw | Philanthropy has to be sustainable

Kiran Mazumdar-Shaw | Philanthropy can catalyse new models for government

Kiran Mazumdar Shaw Explains The Meaning of Atmanirbharta

Kiran Mazumdar-Shaw | Focus on healthcare is driven by justice and compassion

Kiran Mazumdar Shaw’s multi-billion dollar baby

Awfis Space Solutions IPO To Open May 22: Offers Co-working Spaces Nationwide | NDTV Profit

V Guard Ind Q4: Outlook On Growth | NDTV Profit

Biocon Outlook On The Biosimilar Sales | NDTV Profit

How is the Growth Wired For MSWIL? NDTV Profit

Manishi Raychaudhuri Talks Future Of Private Capex and Domestic Market Opportunities

Ideaforge's Order Book Outlook | NDTV Profit

Biocon and HealthCare Global In Focus | Earnings Edge | NDTV Profit

Q1 Review: Biocon's Profit, Margins Fall; Misses Estimates

Q4 Review | Biocon March Quarter Net Profit Soars

Stocks In Focus: Biocon, CG Power and Industrials, LIC & More

Q2 Review: After Weak Q2, Can Biocon Bounce Back In Q3? | BQPrime

Biocon Withdraws Drug Application With EMA